102 related articles for article (PubMed ID: 17459932)
1. Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors.
Pauwels F; Mostmans W; Quirynen LM; van der Helm L; Boutton CW; Rueff AS; Cleiren E; Raboisson P; Surleraux D; Nyanguile O; Simmen KA
J Virol; 2007 Jul; 81(13):6909-19. PubMed ID: 17459932
[TBL] [Abstract][Full Text] [Related]
2. RNA-dependent RNA polymerases from different hepatitis C virus genotypes reveal distinct biochemical properties and drug susceptibilities.
May MM; Lorengel H; Kreuter J; Zimmermann H; Ruebsamen-Schaeff H; Urban A
Biochim Biophys Acta; 2011 Oct; 1814(10):1325-32. PubMed ID: 21621653
[TBL] [Abstract][Full Text] [Related]
3. Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate.
Slater MJ; Amphlett EM; Andrews DM; Bravi G; Burton G; Cheasty AG; Corfield JA; Ellis MR; Fenwick RH; Fernandes S; Guidetti R; Haigh D; Hartley CD; Howes PD; Jackson DL; Jarvest RL; Lovegrove VL; Medhurst KJ; Parry NR; Price H; Shah P; Singh OM; Stocker R; Thommes P; Wilkinson C; Wonacott A
J Med Chem; 2007 Mar; 50(5):897-900. PubMed ID: 17269759
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase.
Delang L; Froeyen M; Herdewijn P; Neyts J
Antiviral Res; 2012 Jan; 93(1):30-8. PubMed ID: 22033247
[TBL] [Abstract][Full Text] [Related]
5. Identification of small molecule inhibitors of the hepatitis C virus RNA-dependent RNA polymerase from a pyrrolidine combinatorial mixture.
Burton G; Ku TW; Carr TJ; Kiesow T; Sarisky RT; Lin-Goerke J; Baker A; Earnshaw DL; Hofmann GA; Keenan RM; Dhanak D
Bioorg Med Chem Lett; 2005 Mar; 15(6):1553-6. PubMed ID: 15745795
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel HCV RNA-dependent RNA polymerase inhibitors using pharmacophore-guided virtual screening.
Kim J; Kim KS; Kim DE; Chong Y
Chem Biol Drug Des; 2008 Dec; 72(6):585-91. PubMed ID: 19090925
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological characterization of B-ring amino analogues of potent benzothiadiazine hepatitis C virus polymerase inhibitors.
Randolph JT; Flentge CA; Huang PP; Hutchinson DK; Klein LL; Lim HB; Mondal R; Reisch T; Montgomery DA; Jiang WW; Masse SV; Hernandez LE; Henry RF; Liu Y; Koev G; Kati WM; Stewart KD; Beno DW; Molla A; Kempf DJ
J Med Chem; 2009 May; 52(10):3174-83. PubMed ID: 19402666
[TBL] [Abstract][Full Text] [Related]
8. Modification of hepatitis C virus 1b RNA polymerase to make a highly active JFH1-type polymerase by mutation of the thumb domain.
Weng L; Du J; Zhou J; Ding J; Wakita T; Kohara M; Toyoda T
Arch Virol; 2009; 154(5):765-73. PubMed ID: 19340394
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.
Thibeault D; Bousquet C; Gingras R; Lagacé L; Maurice R; White PW; Lamarre D
J Virol; 2004 Jul; 78(14):7352-9. PubMed ID: 15220408
[TBL] [Abstract][Full Text] [Related]
10. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.
Lodrini S; Bagaglio S; Canducci F; De Mitri MS; Andreone P; Loggi E; Lazzarin A; Clementi M; Morsica G
J Biol Regul Homeost Agents; 2003; 17(2):198-204. PubMed ID: 14518724
[TBL] [Abstract][Full Text] [Related]
11. [Hepatitis c virus genotype research by ABC programs of 5'-NCR restriction endonuclease digestion].
Qiu GH; Du SC; Sun NX; You P; Fan XF; Zhang YX; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2004 Apr; 12(4):237-9. PubMed ID: 15099479
[TBL] [Abstract][Full Text] [Related]
12. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy.
Kurosaki M; Enomoto N; Murakami T; Sakuma I; Asahina Y; Yamamoto C; Ikeda T; Tozuka S; Izumi N; Marumo F; Sato C
Hepatology; 1997 Mar; 25(3):750-3. PubMed ID: 9049230
[TBL] [Abstract][Full Text] [Related]
13. Identification of non-macrocyclic small molecule inhibitors against the NS3/4A serine protease of hepatitis C virus through in silico screening.
Chaudhuri R; Lee H; Truong L; Torres J; Patel K; Johnson ME
J Chem Inf Model; 2012 Aug; 52(8):2245-56. PubMed ID: 22697413
[TBL] [Abstract][Full Text] [Related]
14. From natural product-inspired pyrrolidine scaffolds to the development of new human Golgi α-mannosidase II inhibitors.
Cheng TJ; Chan TH; Tsou EL; Chang SY; Yun WY; Yang PJ; Wu YT; Cheng WC
Chem Asian J; 2013 Nov; 8(11):2600-4. PubMed ID: 23943613
[No Abstract] [Full Text] [Related]
15. Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance.
Eltahla AA; Luciani F; White PA; Lloyd AR; Bull RA
Viruses; 2015 Sep; 7(10):5206-24. PubMed ID: 26426038
[TBL] [Abstract][Full Text] [Related]
16. Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders.
Eltahla AA; Tay E; Douglas MW; White PA
Antimicrob Agents Chemother; 2014 Dec; 58(12):7215-24. PubMed ID: 25246395
[TBL] [Abstract][Full Text] [Related]
17. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.
Lemm JA; Liu M; Gentles RG; Ding M; Voss S; Pelosi LA; Wang YK; Rigat KL; Mosure KW; Bender JA; Knipe JO; Colonno R; Meanwell NA; Kadow JF; Santone KS; Roberts SB; Gao M
Antimicrob Agents Chemother; 2014 Jun; 58(6):3485-95. PubMed ID: 24733465
[TBL] [Abstract][Full Text] [Related]
18. In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor.
Voitenleitner C; Crosby R; Walker J; Remlinger K; Vamathevan J; Wang A; You S; Johnson J; Woldu E; Van Horn S; Horton J; Creech K; Shotwell JB; Hong Z; Hamatake R
Antimicrob Agents Chemother; 2013 Nov; 57(11):5216-24. PubMed ID: 23939896
[TBL] [Abstract][Full Text] [Related]
19. Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection.
Wyles DL
Top Antivir Med; 2012; 20(4):139-45. PubMed ID: 23154254
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.
Bartels DJ; Sullivan JC; Zhang EZ; Tigges AM; Dorrian JL; De Meyer S; Takemoto D; Dondero E; Kwong AD; Picchio G; Kieffer TL
J Virol; 2013 Feb; 87(3):1544-53. PubMed ID: 23152524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
